Meningococcal infections at the start of the 21st century

Advances in Pediatrics

Volumn 52, Issue , 2005, Pages 129-162

  Brandtzaeg, Petter ^a,b   Van Deuren, Marcel ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDEMIC; HEALTH; HUMAN; MENINGOCOCCOSIS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PATHOGENICITY; REVIEW; STATISTICS;

DISEASE OUTBREAKS; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; WORLD HEALTH;

EID: 24644455976     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2005.03.005     Document Type: Article

References (156)

1. Vieusseux M: Mémoire sur la maladie qui régné a Genève au printemps de 1805. J Med Chir Pharm 11:163-182, 1805.
2. Danielson L, Mann E: The history of a singular and very mortal disease which lately made its appearance in Medfield. Med Agric Reg 1:65, 1806.
3. Weichselbaum A: Ueber die Aetiologie der akuten Meningitis cerebrospinalis. Fortsch Med 5:573-583, 1887.
4. Yazdankhah SP, Caugant DA: Neisseria meningitidis: An overview of the carriage state. J Med Microbiol 53:821-832, 2004.
5. Parkhill J, Achtman M, James KD, et al: Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404:502-506, 2000.
6. Tettelin H, Saunders NJ, Heidelberg J, et al: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287:1809-1815, 2000.
7. Zähringer U, Lindner B, Rietschel ET: Chemical structure of lipid A: Recent advances in structural analysis of biologically active molecules, in Brade H, Opal S, Vogel SN, et al (eds): Endotoxin in Health and Disease. New York, Marcel Dekker, 1999, pp 93-114.
8. Alexander C, Rietschel ET: Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7:167-202, 2001.
9. Kulshin VA, Zähringer U, Lindner B, et al: Structural characterization of the lipid A component of pathogenic Neisseria meningitidis. J Bacterial 174:1793-1800, 1992.
10. Zughaier SM, Tzeng YL, Zimmer SM, et al: Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 72:371-380, 2004.
11. Mcleod Griffiss J, Schmeider H: The chemistry and biology of lipooligosaccharides: The endotoxins of bacteria of the respiratory and genital mucosa, in Brade H, Opal S, Vogel SN, et al (eds): Endotoxin in Health and Disease. New York, Marcel Dekker, 1999, pp 179-194.
12. Kahler CM, Stephens DS: Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 24:281-334, 1998.
13. Jones DM, Borrow R, Fox AJ, et al: The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 13:219-224, 1992.
14. Hood DW, Moxon ER: Lipopolysaccharide phase variation in Haemophilus and Neisseria, in Brade H, Opal S, Vogel SN, et al (eds): Endotoxin in Health and Disease. New York, Marcel Dekker, 1999, pp 39-54.
15. Scholten RJ, Kuipers B, Valkenburg HA, et al: Lipooligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol 41:236-243, 1994.
16. de Vries FP, van der Ende A, van Putten JP, et al: Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect Immun 64:2998-3006, 1996.
17. Giardina PC, Apicella MA: Antigenic mimicry in Neisseria species in Brade H, Opal S, Vogel SN, et al (eds): Endotoxin in Health and Disease. New York, Marcel Dekker, 1999, pp 55-65.
18. Frasch CE, Zollinger WD, Poolman JT: Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504-510, 1985.
19. Poolman JT, Abdillahi H: Outer membrane protein serosubtyping of Neisseria meningitidis. Eur J Clin Microbiol Infect Dis 7:291-292, 1988.
20. Pizza M, Scarlato V, Masignani V, et al: Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816-1820, 2000.
21. Kallstrom H, Liszewski MK, Atkinson JP, et al: Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol 25:639-647, 1997.
22. Kallstrom H, Islam MS, Berggren PO, et al: Cell signaling by the type IV pili of pathogenic Neisseria. J Biol Chem 273:21777-21782, 1998.
23. Plant L, Asp V, Lovkvist L, et al: Epithelial cell responses induced upon adherence of pathogenic Neisseria. Cell Microbiol 6:663-670, 2004.
24. Caugant DA: Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106:505-525, 1998.
25. Pollard AJ, Scheifele D, Rosenstein N: Epidemiology of meningococcal disease in North America, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease, Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 341-356.
26. Raghunathan PL, Bernhardt SA, Rosenstein NE: Opportunities for control of meningococcal disease in the United States. Annu Rev Med 55:333-353, 2004.
27. Maiden MC, Frosch M: Molecular techniques for the investigation of meningococcal disease epidemiology. Mol Biotechnol 18:119-134, 2001.
28. Cartwright K: Meningococcal carriage and disease, in Cartwright K (ed): Meningococcal Disease. Chichester, UK, Wiley, 1995, pp 115-146.
29. Stephens DS, Farley MM: Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 13:22-33, 1991.
30. Read RC, Fox AJ, Miller K, et al: Experimental infection of human nasal mucosal explants with Neisseria meningitidis. J Med Microbiol 42:353-361, 1995.
31. Dinarello CA: Infection, fever, and exogenous and endogenous pyrogens: Some concepts have changed. J Endotoxin Res 10:201-222, 2004.
32. Brandtzaeg P, Bjerre A, Ovstebo R, et al: Neisseria meningitidis lipopolysaccharides in human pathology. J Endotoxin Res 7:401-420, 2001.
33. Brandtzaeg P, Kierulf P, Gaustad P, et al: Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195-204, 1989.
34. Brandtzaeg P, Ovstebo R, Kierulf P: Quantitative detection of bacterial lipopolysaccharides in clinical specimen, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease, Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 427-439.
35. Steeghs L, den Hartog R, den Boer A, et al: Meningitis bacterium is viable without endotoxin. Nature 392:449-450, 1998.
36. Uronen H, Williams AJ, Dixon G, et al: Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS). Clin Exp Immunol 122:312-315, 2000.
37. van der Ley P, Steeghs L: Lessons from an LPS-deficient Neisseria meningitidis mutant. J Endotoxin Res 9:124-128, 2003.
38. Brandtzaeg P: Host response to Neisseria meningitidis lacking lipopolysaccharides. Expert Rev Anti Infect Ther 1:589-596, 2003.
39. Ingalls RR, Lien E, Golenbock DT: Differential roles of TLR2 and TLR4 in the host response to Gram-negative bacteria: Lessons from a lipopolysaccharide- deficient mutant of Neisseria meningitidis. J Endotoxin Res 6:411-415, 2000.
40. Ingalls RR, Lien E, Golenbock DT: Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun 69:2230-2236, 2001.
41. Pridmore AC, Wyllie DH, Abdillahi F, et al: A lipopolysaccharide- deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 183:89-96, 2001.
42. Sprong T, Stikkelbroeck N, van der Ley P, et al: Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J Leukoc Biol 70:283-288, 2001.
43. Tobias PS, Tapping RI, Gegner JA: Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis 28:476-481, 1999.
44. Miyake K: Endotoxin recognition molecules, Toll-like receptor 4-MD-2. Semin Immunol 16:11-16, 2004.
45. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 4:499-511, 2004.
46. Mirlashari MR, Lyberg T: Expression and involvement of Toll-like receptors (TLR)2, TLR4, and CD14 in monocyte TNF-alpha production induced by lipopolysaccharides from Neisseria meningitidis. Med Sci Monit 9:BR316-324, 2003.
47. Bjerre A, Brusletto B, Ovstebo R, et al: Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the CD14-TLR4 receptor complex. J Endotoxin Res 9:155-163, 2003.
48. Brandtzaeg P, Mollnes TE, Kierulf P: Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160:58-65, 1989.
49. Bjerre A, Brusletto B, Mollnes TE, et al: Complement activation induced by purified Neisseria meningitidis lipopolysaccharide (LPS), outer membrane vesicles, whole bacteria, and an LPS-free mutant. J Infect Dis 185:220-228, 2002.
50. Sprong T, Moller AS, Bjerre A, et al: Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect Immun 72:3344-3349, 2004.
51. Brandtzaeg P, Hogasen K, Kierulf P, et al: The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173:647-655, 1996.
52. Sprong T, Brandtzaeg P, Fung M, et al: Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102:3702-3710, 2003.
53. Hazelzet JA, de Groot R, van Mierlo G, et al: Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 66:5350-5356, 1998.
54. Emonts M, Hazelzet JA, de Groot R, et al: Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3:565-577, 2003.
55. Hackett SJ, Guiver M, Marsh J, et al: Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child 86:44-46, 2002.
56. Ovstebo R, Brandtzaeg P, Brusletto B, et al: Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 42:2980-2987, 2004.
57. van Deuren M, Brandtzaeg P, van der Meer JW: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13:144-166, 2000.
58. Nassif X, Bourdoulous S, Eugene E, et al: How do extracellular pathogens cross the blood-brain barrier? Trends Microbiol 10:227-232, 2002.
59. Brandtzaeg P, Ovstebo R, Kierulf P: Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 166:650-652, 1992.
60. Warren HS, Gonzalez RG, Tian D: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2003. A 12-year-old girl with fever and coma. N Engl J Med 349:2341-2349, 2003.
61. Sullivan TD, LaScolea LJ: Neisseria meningitidis bacteremia in children: Quantitation of bacteremia and spontaneous clinical recovery without antibiotic therapy. Pediatrics 80:63-67, 1987.
62. Wuillemin WA, Fijnvandraat K, Derkx BH, et al: Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 74:1436-1441, 1995.
63. O'Brien JM, Abraham E: Human models of endotoxemia and recombinant human activated protein C. Crit Care Med 32:8202-3208, 2004.
64. Fijnvandraat K, Derkx B, Peters M, et al: Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15-20, 1995.
65. Derhaschnig U, Reiter R, Knobl P, et al: Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102:2093-2098, 2003.
66. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
67. Waage A, Aasen AO: Different role of cytokine mediators in septic shock related to meningococcal disease and surgery/polytrauma. Immunol Rev 127:221-230, 1992.
68. Bjerre A, Brusletto B, Hoiby EA, et al: Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic gram-positive septic shock. Crit Care Med 32:433-438, 2004.
69. Liaw PC, Esmon CT, Kahnamoui K, et al: Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 104:3958-3964, 2004.
70. de Kleijn ED, de Groot R, Hack CE, et al: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839-1847, 2003.
71. Macias WL, Nelson DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32:S223-S228, 2004.
72. Sorensen HT, Nielsen GL, Schonheyder HC, et al: Outcome of pre-hospital antibiotic treatment of meningococcal disease. J Clin Epidemiol 51:717-721, 1998.
73. White B, Livingstone W, Murphy C, et al: An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719-3724, 2000.
74. Kuppermann N, Malley R, Inkelis SH, et al: Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics 103:E20, 1999.
75. Inkelis SH, O'Leary D, Wang VJ, et al: Extremity pain and refusal to walk in children with invasive meningococcal disease. Pediatrics 110:e3, 2002.
76. Nielsen HE, Andersen EA, Andersen J, et al: Diagnostic assessment of haemorrhagic rash and fever. Arch Dis Child 85:160-165, 2001.
77. Wells LC, Smith JC, Weston VC, et al: The child with a non-blanching rash: How likely is meningococcal disease? Arch Dis Child 85:218-222, 2001.
78. Riordan FA, Marzouk O, Thomson AP, et al: Prospective validation of the Glasgow Meningococcal Septicaemia Prognostic Score. Comparison with other scoring methods. Eur J Pediatr 161:531-537, 2002.
79. Festa M, Derkx B: Clinical scoring systems in meningococcal disease, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease, Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 411-425.
80. Kornelisse RF, Hazelzet JA, Hop WCJ, et al: Meningococcal septic shock in children: Clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 25:640-646, 1997.
81. Peters MJ, Ross-Russell RI, White D, et al: Early severe neutropenia and thrombocytopenia identifies the highest risk cases of severe meningococcal disease. Pediatr Crit Care Med 2:225-231, 2001.
82. Leclerc F, Delepoulle F, Diependaele JF, et al: Severity scores in meningococcal septicemia and severe infectious purpura with shock. Intensive Care Med 21:264-265, 1995.
83. Nadel S, Levin M, Habibi P: Treatment of meningococcal disease in childhood, in Cartwright K (ed): Meningococcal Disease. Chichester, UK, Wiley, 1995, pp 207-243.
84. Pollard AJ, Britto J, Nadel S, et al: Emergency management of meningococcal disease. Arch Dis Child 80:290-296, 1999.
85. Welch SB, Nadel S: Treatment of meningococcal infection. Arch Dis Child 88:608-614, 2003.
86. Nadel S, Macinthosh I, Levin M: Evaluation of new treatment in meningococcal disease, in Pollard AJ, Maiden MCJ (eds): Meningococal Disease. Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 549-586.
87. Booy R, Habibi P, Nadel S, et al: Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 85:386-390, 2001.
88. Goldacre MJ, Roberts SE, Yeates D: Case fatality rates for meningococcal disease in an English population, 1963-98: Database study. BMJ 327:596-597, 2003.
89. Kanegaye JT, Soliemanzadeh P, Bradley JS: Lumbar puncture in pediatric bacterial meningitis: Defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 108:1169-1174, 2001.
90. van Deuren M, van Dijke BJ, Koopman RJ, et al: Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions. BMJ 306:1229-1232, 1993.
91. Quagliarello VJ, Scheld WM: Treatment of bacterial meningitis. N Eng J Med 336:708-716, 1997.
92. Ellis-Pegler R, Galler L, Roberts S, et al: Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. Clin Infect Dis 37:658-662, 2003.
93. Cartwright KA: Early management of meningococcal disease. Infect Dis Clin North Am 13:661-684, 1999.
94. van Deuren M, Brandtzaeg P: Cytokine measurement in vivo and in vitro, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease. Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 459-486.
95. Guiver M, Borrow R: PCR diagnosis, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease. Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 23-39.
96. Sobanski MA, Barnes RA, Coakley WT: Detection of meningococcal antigen by latex agglutination, in Pollard AJ, Maiden MCJ (eds): Meningococcal Disease. Methods and Protocols. Totowa, NJ, Humana Press, 2001, pp 41-59.
97. Talan DA, Guterman JJ, Overturf GD, et al: Analysis of emergency department management of suspected bacterial meningitis. Ann Emerg Med 18:856-862, 1989.
98. Wood AL, O'Brien SJ: How long is too long? Determining the early management of meningococcal disease in Birmingham. Public Health 110:237-239, 1996.
99. Riordan FA: Improving promptness of antibiotic treatment in meningococcal disease. Emerg Med J 18:162-163, 2001.
100. Davies MS, Nadel S, Habibi P, et al: The orthopaedic management of peripheral ischaemia in meningococcal septicaemia in children. J Bone Joint Surg Br 82:383-386, 2000.
101. Romijn JA, Godfried MH, Wortel C, et al: Hypoglycemia, hormones and cytokines in fatal meningococcal septicemia. J Endocrinol Invest 13:743-747, 1990.
102. Baines PB, Thomson AP, Fraser WD, et al: Hypocalcaemia in severe meningococcal infections. Arch Dis Child 83:510-513, 2000.
103. van Deuren M, Neeleman C, Assmann KJM, et al: Rhabdomyolysis during the subacute stage of meningococcal sepsis. Clin Infect Dis 26:214-215, 1998.
104. van Deuren M, Santman FW, van Dalen R, et al: Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15:424-430, 1992.
105. Best C, Walsh J, Sinclair J, et al: Early haemo-diafiltration in meningococcal septicaemia. Lancet 347:202, 1996.
106. van Deuren M, van der Meer JW: Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically. Intensive Care Med 26:1176-1178, 2000.
107. de Chalain T, Cohen SR, Burstein FD: Successful use of leeches in the treatment of purpura fulminans. Ann Plast Surg 35:300-306, 1995.
108. Aiuto LT, Barone SR, Cohen PS, et al: Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 25:1079-1082, 1997.
109. Veldman A, Ehrenberg A, Jager G, et al: Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura? Crit Care Med 28:598-600, 2000.
110. Zenz W, Zoehrer B, Levin M, et al: Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: A retrospective study. Crit Care Med 32:1777-1780, 2004.
111. Barton P, Kalil AC, Nadel S, et al: Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 113:7-17, 2004.
112. Hardman JM, Earle KM: Meningococcal infections: A review of 200 fatal cases. J Neuropathol Exp Neurol 26:119, 1967.
113. Dinakaran S, Chan TK, Rogers NK, et al: Retinal hemorrhages in meningococcal septicemia. J AAPOS 6:221-223, 2002.
114. Brandtzaeg P, Joo GB, Brusletto B, et al: Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57:271-278, 1990.
115. Fourrier F, Lestavel P, Chopin C, et al: Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 16:121-124, 1990.
116. Cremer R, Leclerc F, Jude B, et al: Are there specific haemostatic abnormalities in children surviving septic shock with purpura and having skin necrosis or limb ischaemia that need skin grafts or limb amputations? Eur J Pediatr 158:127-132, 1999.
117. Kuppermann N, Inkelis SH, Saladino R: The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 13:867-873, 1994.
118. Fourrier F, Leclerc F, Aidan K, et al: Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: A pharmacokinetic study. Intensive Care Med 29:1081-1087, 2003.
119. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286:1869-1878, 2001.
120. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 290:238-247, 2003.
121. Esmon CT, Xu J, Gu JM, et al: Endothelial protein C receptor. Thromb Haemost 82:251-258, 1999.
122. Kondaveeti S, Hibberd ML, Booy R, et al: Effect of the factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 18:893-896, 1999.
123. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408-416, 2001.
124. Bernard GR, Macias WL, Joyce DE, et al: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 7:155-163, 2003.
125. van Deuren M, Neeleman C, van 't Hek LGFM, et al: A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Med 24:157-161, 1998.
126. Riordan FA, Thomson AP, Ratcliffe JM, et al: Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: Evidence of adrenal insufficiency? Crit Care Med 27:2257-2261, 1999.
127. de Kleijn ED, Joosten KF, van Rijn B, et al: Low serum cortisol in combination with high adrenocorticotrophic hormone concentrations are associated with poor outcome in children with severe meningococcal disease. Pediatr Infect Dis J 21:330-336, 2002.
128. Joosten KF, de Kleijn ED, Westerterp M, et al: Endocrine and metabolic responses in children with meningoccocal sepsis: Striking differences between survivors and nonsurvivors. J Clin Endocrinol Metab 85:3746-3753, 2000.
129. van Woensel JB, Biezeveld MH, Alders AM, et al: Adrenocorticotropic hormone and cortisol levels in relation to inflammatory response and disease severity in children with meningococcal disease. J Infect Dis 184:1532-1537, 2001.
130. van Deuren M, Neeleman C, Bartelink AK: Acute adrenal insufficiency in critically ill patients: The Waterhouse-Friderichsen syndrome revisited, in Vincent JL (eds): Yearbook of Intensive Care. Berlin, Springer-Verlag, 2001, pp 100-109.
131. O'Brien K, Morton NS: Haemodynamic improvement in a child with meningococcal sepsis following methylprednisolone: Restoration of beta-adrenergic receptor responsiveness? Paediatr Anaesth 8:419-420, 1998.
132. Gupta S, Tuladhar AB: Does early administration of dexamethasone improve neurological outcome in children with meningococcal meningitis? Arch Dis Child 89:82-83, 2004.
133. Cuthbertson BH, Dickson R, Mackenzie A: Intracranial pressure measurement, induced hypothermia and barbiturate coma in meningitis associated with intractable raised intracranial pressure. Anaesthesia 59:908-911, 2004.
134. Greenwood BM, Mohammed I, Whittle HC: Immune complexes and the pathogenesis of meningococcal arthritis. Clin Exp Immunol 59:513-519, 1985.
135. El Bashir H, Klaber R, Mukasa T, et al: Pericarditis after meningococcal infection: Case report of a child with two distinct episodes. Pediatr Infect Dis J 23:279-281, 2004.
136. Wheeler JS, Anderson BJ, De Chalain TM: Surgical interventions in children with meningococcal purpura fulminans: A review of 117 procedures in 21 children. J Pediatr Surg 38:597-603, 2003.
137. Harley OJ, Ahmed OA, Ng RL: Imaging to guide amputation of necrotic limbs in paediatric patients with meningococcal septicaemia. Br J Plast Surg 57:174-175, 2004.
138. van de Beek D, de Gans J: Meningitis-associated hearing loss: Protection by adjunctive antioxidant therapy. Ann Neurol 55:597-598, 2004.
139. Oostenbrink R, Maas M, Moons KG, et al: Sequelae after bacterial meningitis in childhood. Scand J Infect Dis 34:379-382, 2002.
140. Berg S, Trollfors B, Hugosson S, et al: Long-term follow-up of children with bacterial meningitis with emphasis on behavioural characteristics. Eur J Pediatr 161:330-336, 2002.
141. Purcell B, Samuelsson S, Hahne SJ, et al: Effectiveness of antibiotics in preventing meningococcal disease after a case: Systematic review. BMJ 328:1339, 2004.
142. Gilmore A, Stuart J, Andrews N: Risk of secondary meningococcal disease in health-care workers. Lancet 356:1654-1655, 2000.
143. American Academy of Pediatrics. Meningococcal infections, in Pickering LK (ed): Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003, pp 430-436.
144. Ison CA, Anwar N, Cole MJ, et al: Age dependence of in vitro survival of meningococci in whole blood during childhood. Pediatr Infect Dis J 22:868-873, 2003.
145. Platonov AE, Vershinina IV, Kayhty H, et al: Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients. Int Arch Allergy Immunol 130:314-321, 2003.
146. MacLennan J, Obaro S, Deeks J, et al: Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 183:97-104, 2001.
147. Snape MD, Pollard AJ: Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5:21-30, 2005.
148. Maiden MC, Stuart JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359:1829-1831, 2002.
149. de Moreas JC, Perkins BA, Camargo MC, et al: Protective efficacy of a serogroup B meningococcal vaccine in San Paulo, Brazil. Lancet 340:1074-1078, 1992.
150. O'Hallahan J, Lennon D, Oster P: The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr Infect Dis J 23:S293-S298, 2004.
151. de Kleijn E, van Eijndhoven L, Vermont C, et al: Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20:352-358, 2001.
152. The J5 Study Group: Treatment of severe infectious purpura in children with plasma from donors immunized with Escherichia coli J5: A prospective double-blind study. J Infect Dis 165:695-701, 1992.
153. Derkx B, Wittes J, McCloskey R: Randomized placebo-controlled trial of HA-1A, a human monoclonal anti-endotoxin antibody, in children with meningococcal septic shock. Clin Infect Dis 28:770-777, 1999.
154. Levin M, Quint PA, Goldstein B, et al: Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. Lancet 356:961-967, 2000.
155. van Deuren M, Brandtzaeg P: Parents' and GPs' key role in diagnosis of meningococcal septicaemia. Lancet 356:954-955, 2000.
156. Jansen PM, Pixley RA, Brouwer M, et al: Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87:2337-2344, 1996.